EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors

Ahmet Yildirim iD, Mengting Wei, Yuan Liu, Bassel Nazha, Jacqueline T Brown, Bradley C Carthon, Yujin Choi, Lauren Suh, Rohit V Goswamy, Greta R McClintock, Caitlin Hartman, Sarah Caulfield und 6 weitere

Therapeutic Advances in Medical Oncology · 2025-01 · 17

DOI: 10.1177/17588359251316243 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 12.02.2025. Verfasst von Ahmet Yildirim und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: NCI NIH HHS, Winship Cancer Institute, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Immune checkpoint inhibitors (ICIs) have become the mainstay treatment of metastatic kidney cancer, demonstrating enhanced outcomes and durable responses in select patient subgroups. However, identifying reliable prognostic biomarkers for treatment outcomes remains challenging.

Objectives

This study aimed to assess the correlation between baseline inflammatory markers and overall survival (OS), progression-free survival (PFS), and clinical benefit (CB) in metastatic kidney cancer patients receiving ICIs. CB was defined as patients achieving stable disease, partial response, or complete response.

Design

Retrospective, single-center study.

Methods

A retrospective analysis was conducted on 401 adult patients with advanced kidney cancer treated with ICIs at Emory Winship Cancer Institute between 2018 and 2023. Modified Glasgow Prognostic Score (mGPS), neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), platelet-to-lymphocyte (PLR), and neutrophil-to-eosinophil ratios (NER) were collected from baseline blood samples.

Results

Among 401 patients (median age, 66; 71% male; 21% Black/African American), median follow-up was 43.0 months (95% CI, 36.6–51.4). Patients with mGPS scores of 0 had longer OS than those with a score of 1 (hazard ratio (HR), 0.38; 95% CI, 0.23–0.62; p < 0.001) and 2 (HR, 0.37; 95% CI, 0.20–0.67; p = 0.001), and longer PFS compared to patients with mGPS scores of 1 (HR, 0.66; 95% CI, 0.44–0.98; p = 0.039) and 2 (HR, 0.44; 95% CI, 0.29–0.67; p < 0.001). Low baseline NLR was associated with longer PFS (HR, 0.73; 95% CI, 0.54–0.97; p = 0.032). Low baseline MLR correlated with improved OS (HR, 0.60; 95% CI, 0.44–0.83; p = 0.002) and PFS (HR, 0.73; 95% CI, 0.55–0.97; p = 0.031). Similarly, low baseline PLR was associated with higher CB likelihood (odds ratio (OR), 2.20; 95% CI, 1.31–3.69; p = 0.003), and low baseline NER was linked to improved OS (HR, 0.63; 95% CI, 0.46–0.87; p = 0.004), PFS (HR, 0.67; 95% CI, 0.51–0.88; p = 0.003), and higher CB (OR, 2.04; 95% CI, 1.20–3.46; p = 0.008).

Conclusion

Lower levels of systemic inflammatory markers are associated with more favorable clinical outcomes with ICI treatment. Prospective studies are needed for further validation.

Schlagwörter

Stichwörter der Autor:innen

biomarkerscheckpoint inhibitorsimmunotherapyinflammationinflammatory biomarkersrenal cell carcinoma

Autor:innen und Institutionen

  • Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA, USA.
  • Emory University, Atlanta, GA, USA.
  • Departments of Biostatistics and Bioinformatics, Emory University, Atlanta, GA, USA.
  • Winship Cancer Institute of Emory University, Atlanta, GA, USA.
  • University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
  • Department of Pharmaceutical Services, Emory University School of Medicine, Atlanta, GA, USA.

ORCID-Profile: Ahmet Yildirim, Mehmet A Bilen

Förderung

  • NCI NIH HHS
  • Winship Cancer Institute
  • National Cancer Institute

Zitieren

APA

Yildirim, A., Wei, M., Liu, Y., Nazha, B., Brown, J. T., Carthon, B. C., Choi, Y., Suh, L., Goswamy, R. V., McClintock, G. R., Hartman, C., Caulfield, S., Ciuro, J., Goldman, J. M., Harris, W. B., Kucuk, O., Master, V. A., & Bilen, M. A. (2025). Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology, 17. https://doi.org/10.1177/17588359251316243

Vancouver

Yildirim A, Wei M, Liu Y, Nazha B, Brown JT, Carthon BC, et al. Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors. Therapeutic Advances in Medical Oncology. 2025;17. doi:10.1177/17588359251316243

BibTeX
@article{Yildirim2025,
  author = {Yildirim, Ahmet and Wei, Mengting and Liu, Yuan and Nazha, Bassel and Brown, Jacqueline T and Carthon, Bradley C and Choi, Yujin and Suh, Lauren and Goswamy, Rohit V and McClintock, Greta R and Hartman, Caitlin and Caulfield, Sarah and Ciuro, Jordan and Goldman, Jamie M and Harris, Wayne B and Kucuk, Omer and Master, Viraj A and Bilen, Mehmet A},
  title = {Association of baseline inflammatory biomarkers and clinical outcomes in patients with advanced renal cell carcinoma treated with immune checkpoint inhibitors},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2025},
  volume = {17},
  doi = {10.1177/17588359251316243}
}
Kostenlos starten →